Strongbridge Biopharma (SBBP) Stock Forecast, Price & News

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Strongbridge Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBBP, but not buy additional shares or sell existing shares.
View analyst ratings for Strongbridge Biopharma or view top-rated stocks.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to the consensus estimate of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.
View Strongbridge Biopharma's earnings history.

What price target have analysts set for SBBP?

2 brokers have issued 1-year target prices for Strongbridge Biopharma's shares. Their forecasts range from $3.25 to $3.25. On average, they expect Strongbridge Biopharma's stock price to reach $3.25 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:

• John H. Johnson, Chief Executive Officer & Director
• Richard S. Kollender, President & Chief Financial Officer
• Fredric Cohen, Chief Medical Officer
• Brian Conner, Chief Compliance Officer
• Peter J. Valentinsson, Senior Vice President-Global Technical Operations

Who are some of Strongbridge Biopharma's key competitors?

Some companies that are related to Strongbridge Biopharma include Bicycle Therapeutics (BCYC), POINT Biopharma Global (PNT), Geron (GERN), Collegium Pharmaceutical (COLL), Day One Biopharmaceuticals (DAWN), SIGA Technologies (SIGA), Centessa Pharmaceuticals (CNTA), Amylyx Pharmaceuticals (AMLX), ANI Pharmaceuticals (ANIP), Pharming Group (PHAR), Amryt Pharma (AMYT), Foghorn Therapeutics (FHTX), Zealand Pharma A/S (ZEAL), Praxis Precision Medicines (PRAX) and Tango Therapeutics (TNGX).
View all of SBBP's competitors.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected].